Should you let pets sleep next to you? (Does it even matter what the experts say?)
It turns out, our furry best friend might be our sleep enemy.
Lots of pet owners let their animals sleep on the bed with them, which usually disrupts sleep . But many would say it's worth it.
And researchers don't necessarily disagree.
Melissa Milanak, a professor at Medical University of South Carolina specializing in sleep health, said most people at her clinic say their pets disturb them often at night.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Nivolumab Plus Chemotherapy Improves Survival in Lung Cancer
Adding nivolumab to neoadjuvant chemotherapy significantly improved 5-year overall survival among patients with resectable non-small cell lung cancer (NSCLC), according to findings from a phase 3 trial presented at the recent American Society of Clinical Oncology (ASCO) 2025 annual meeting. The survival benefit was more pronounced in patients who achieved a pathologic complete response or a presurgery clearance of circulating tumor DNA (ctDNA). METHODOLOGY: The phase 3 CheckMate 816 trial has shown that compared with neoadjuvant chemotherapy alone, nivolumab plus chemotherapy improvespathologic complete response rates and event-free survival in patients with stage IB-IIIA resectable NSCLC. Based on these findings, this regimen was approved for this patient population in the US, EU, and other places. compared with neoadjuvant chemotherapy alone, nivolumab plus chemotherapy improvespathologic complete response rates and event-free survival in patients with stage IB-IIIA resectable NSCLC. Based on these findings, this regimen was approved for this patient population in the US, EU, and other places. Researchers are now reporting the final, prespecified analysis of overall survival. In the trial, 358 patients with stage IB-IIIA resectable NSCLC were randomly assigned to receive either nivolumab plus platinum-based chemotherapy or platinum-based chemotherapy alone every 3 weeks for three cycles. Surgery was performed within 6 weeks of completing neoadjuvant treatment. Postoperative adjuvant chemotherapy, radiotherapy, or both were permitted. Primary endpoints were event-free survival and pathologic complete response. Overall survival was the key secondary endpoint. The median follow-up duration was 68.4 months. TAKEAWAY: The 5-year overall survival rate was 65.4% with nivolumab plus chemotherapy vs 55.0% with chemotherapy alone. Nivolumab plus chemotherapy reduced the risk for death by 28% (hazard ratio [HR], 0.72; P = .048). = .048). Among patients who received the combination therapy, the 5-year overall survival rate was 95.3% for those who achieved a pathological complete response vs 55.7% for those who did not. Overall, 24% of patients in the nivolumab group achieved a pathological complete response vs only 2.2% in the chemotherapy group. ctDNA clearance before surgery was a strong prognostic indicator, regardless of treatment. At 5 years, overall survival was 75.0% among patients with ctDNA clearance vs 52.6% in those without (HR for death, 0.38 in the nivolumab group and 0.39 in the chemotherapy-only group). The combination therapy was associated with consistent survival benefits across disease stage and PDL-1 expression levels. The 5-year lung cancer-specific survival rate was 74.9% with nivolumab plus chemotherapy vs 65.1% with chemotherapy alone (HR, 0.65). No new safety concerns emerged, and there were no new deaths related to a trial treatment. IN PRACTICE: 'In this trial, we found that the use of neoadjuvant nivolumab plus chemotherapy resulted in significantly longer overall survival than chemotherapy alone, along with long-term benefit regarding event-free survival,' the authors wrote. 'These findings support the hypothesis that neoadjuvant chemoimmunotherapy can have a profound impact on the course of a patient's life when paired with the curative potential of surgical resection.' SOURCE: This study, led by Patrick M. Forde, MB, BCh, PhD, Trinity St. James's Cancer Institute, Trinity College Dublin, Dublin, Ireland, was published online in The New England Journal of Medicine and presented at ASCO. LIMITATIONS: Although the overall survival with nivolumab plus chemotherapy achieved statistical significance, the margin was narrow. Additionally, several subgroups in the exploratory analyses were too small for adequate statistical comparison, requiring cautious interpretation of these results. Black patients were underrepresented, which may have affected the generalizability of the findings. DISCLOSURES: This study was funded by Bristol Myers Squibb. Five authors declared being employees of Bristol Myers Squibb, with some holding stock or stock options with the company. Several authors declared working as consultants or having other ties with various sources including Bristol Myers Squibb.
Geek Girl Authority
an hour ago
- Geek Girl Authority
SPACEBALLS Sequel and Key Cast Members Announced
Mel Brooks has shared that Spaceballs 2 is on the horizon. Spaceballs 2 The announcement comes in the form of a brief trailer, which you can watch below. In addition to Brooks reprising his role, Rick Moranis and Bill Pullman are also returning. The legendary Mel Brooks has announced that one of the most beloved comedy movies of all time is getting a sequel. Spaceballs 2 is on its way and is scheduled to arrive in 2027. Here's what we know so far about the immediately highly anticipated sequel, coming from Amazon MGM+ Studios. Spaceballs 2: The Search for More Money Obviously, with the movie two years away, we only know so much about it at the moment. However, one extremely exciting element we are aware of is several returning cast members. These will include Rick Moranis as Dark Helmet. This casting inclusion is especially exciting because Moranis has so rarely appeared onscreen since taking a sabbatical from acting in 1997. RELATED: Star Trek: Lower Decks : 7 Non-Franchise References But the exciting casting doesn't stop there. Also returning will be Bill Pullman as Lone Starr. And Brooks, who will be 100 years old when the movie debuts, will reprise the role of Yogurt. Joining the cast will be some fresh faces, too, including Keke Palmer. Spaceballs 2 will be written by Benji Samit, Dan Hernandez and Josh Gad. It will be directed by Josh Greenbaum, whose previous work includes the hilarious buddy comedy Barb and Star Go to Vista Del Mar. The original Spaceballs was released in 1987. The comedy is a send-up of Star Wars that also parodies other popular sci-fi franchises. Including, memorably, a singing and dancing version of Alien 's chestburster. It's worth mentioning that, during the original movie, the aforementioned Yogurt did suggest a sequel. His proposed title for the movie was Spaceballs 2: The Search for More Money . RELATED: 8 Star Trek References in the Futurama DVD Movies Spaceballs 2 was announced via a trailer, which you can watch for yourself below. Before an introduction from Brooks, the Spaceballs theme plays. It's accompanied by a blue text crawl that parodies the opening of Star Wars movies. And it points out that many, many genre franchise movies (and shows) have been released since the first Spaceball s . Source: Deadline. The original Spaceballs is currently available for streaming on HBO Max. STAR TREK: STRANGE NEW WORLDS: Paramount Announces Fifth and Final Season Avery Kaplan is the author of several books and the Features Editor at Comics Beat. She was honored to serve as a judge for the 2021 Cartoonist Studio Prize Award and the 2021 Prism Awards. She lives in the mountains of Southern California with her partner and a pile of cats, and her favorite place to visit is the cemetery. You can also find her writing on Comics Bookcase, NeoText, Shelfdust, the Mary Sue, in many issues of PanelxPanel, and in the margins of the books in her personal library.
Medscape
2 hours ago
- Medscape
AMA Calls for ACIP Answers, Stable Federal Funding
Leaders and delegates at this week's American Medical Association (AMA) annual meeting called for more stable funding for medical care and research, and a US Senate investigation into unprecedented changes to a federal vaccine advisory panel. AMA delegates passed an emergency resolution asking for that investigation after US Department of Health and Human Services Secretary Robert F. Kennedy Jr earlier this week removed all 17 members of the Advisory Committee on Immunization Practices (ACIP), replacing them with eight new members, some regarded as vaccine skeptics. The resolution also directs AMA to send a letter asking Kennedy to immediately reverse the changes. Jason M. Goldman, MD, president of the American College of Physicians said at the meeting that Kennedy's action puts at risk insurance coverage for vaccines. ACIP's recommendations influence insurance coverage and vaccine uptake. 'As physicians, we must be the voice for our patients,' said Goldman. 'We must be the voice for science, evidence, and knowledge, and we must make sure that our institutions are protected.' Other delegates pressed the AMA to fight back against deep cuts to federal funding for healthcare and medical research. In his inaugural speech on Tuesday as AMA president, Bobby Mukkamala, MD, an otolaryngologist, said the 'importance of access to physician care is very much on my mind.' 'We cannot lose sight of what medicine and science have achieved in our lifetimes, and we cannot abandon this progress and endanger the health of millions whose illnesses could have been treated had we stayed on course,' Mukkamala said. Congressional Republicans have proposed cutting Medicaid spending and reducing subsidies for plans sold by exchanges created by the Affordable Care Act. Separately, the Trump administration has proposed a roughly 40% cut, or almost $18 billion, in the annual funding of the National Institutes of Health for fiscal 2026, the budget year starting in October. Mukkamala also called for efforts to reduce the administrative burden of prior authorization and to address Medicare physician payments, which have not kept up with inflation in recent years. More Transparency for Artificial Intelligence (AI) in Medicine The AMA also adopted policies regarding AI-driven tools and guidance for physicians regarding corporate investment in their practices. One policy calls for independent third parties to determine whether an AI tool for clinicians is 'explainable' — that it can explain to users its decisions and the evidence behind them. The new AMA policy calls for more transparency regarding these tools, including disclosure of their algorithms. Physicians at the conference raised concerns about AI-based tools making errors that could potentially harm patients and leave clinicians liable for the tools' flaws. AMA members' concerns included the potential for AI hallucinations about billing codes to leave a busy physician at risk for allegations of fraud. Among those who pushed for the AMA to adopt new policies on AI-driven tools was Jennifer Bryan, MD, chair of the Mississippi delegation to the AMA and president of the Mississippi State Medical Association. Decisions made at this AMA meeting will help physicians know when 'AI informs clinical decisions and exactly how confident the AI is in its recommendations,' Bryan told Medscape Medical News in an email. 'This is a big step forward in not just setting standards today but shaping responsible AI practices in medicine for years to come.' Corporate Intrusion The AMA delegates also voted to strengthen guidance for physicians regarding corporate or private equity investment in their practices. Corporate investment can offer an alternative to selling a practice to a hospital or health system, AMA said. These kinds of arrangements can include private or public for-profit companies, investment firms, and insurance companies. Physicians may benefit from these arrangements by being freed of some business and administrative responsibilities to spend more time with patients. But such arrangements may also pose risks, including the loss of independent authority over clinical decisions and operations, the AMA said. AMA's updated guidance recommends that decisions that should remain in the ultimate control of the physicians partnered with other entities include: Determining which diagnostic tests are appropriate for patients. Determining the need for referral or consultation with another clinician. Determining how many patients a physician should see or how many hours a physician should work. Determining the content of patient medical records. Making decisions regarding coding and billing procedures for patient care services.
